ventricular arrhythmias and sudden cardiac death

in review 7 min read Updated 2026-10-30
ventricular arrhythmias and sudden cardiac death

Unstable → shock. Stable monomorphic VT with structural heart disease → DCCV or procainamide. Polymorphic VT → check the QT: normal QT = ischaemia until proven otherwise (cath lab); long QT = torsades → magnesium, K⁺ ≥4, raise the heart rate, stop QT drugs. Wide-complex tachycardia of uncertain origin is VT. Long term: beta-blocker for all, ICD if VT/VF has no reversible cause, sotalol/amiodarone or ablation to suppress recurrences. AADs other than beta-blockers do not improve survival.

sustained VT / electrical storm — admission bundle
  • pulseless or unstable: defibrillate or synchronised DCCV, ACLS
  • shock-refractory VF/pVT: amiodarone 300 mg IV (then 150 mg) or lidocaine 100 mg IV (then 50 mg)
  • stable monomorphic VT: DCCV or procainamide 10 mg/kg over 20 min → 1–2 mg/min
  • stable VT second line: amiodarone 150 mg over 10 min → 1 mg/min × 6 h → 0.5 mg/min × 18 h, or lidocaine 1 mg/kg → 1–2 mg/min
  • polymorphic VT with normal QT or STEMI: urgent angiography; IV beta-blocker, amiodarone or lidocaine
  • torsades: IV magnesium, K⁺ ≥4.0, stop QT-prolonging drugs; overdrive pacing if bradycardic
  • no CCBs for wide-complex tachycardia of unknown origin
  • electrical storm (≥3 episodes in 24 h): non-selective beta-blocker (propranolol 40 mg PO q6h if BP allows) + IV amiodarone
  • electrical storm: sedation, early EP involvement, ablation; amiodarone load 1–2 g over 24 h
  • K⁺ ≥4.0, Mg²⁺ ≥0.9–1.0 mmol/L
  • 12-lead ECG, telemetry, electrolytes, troponin, TTE; interrogate ICD and review programming
  • cause unclear after echo and angiography: CMR
  • treat HF and ischaemia
  • VF/VT without reversible cause: secondary-prevention ICD → ventricular arrhythmias and sudden cardiac death
torsades de pointes

Polymorphic VT with a long QT in sinus beats. Pulseless or unstable → defibrillate.

first
  • magnesium 2 g IV — works even with a normal serum Mg²⁺
  • stop QT-prolonging drugs; K⁺ to ≥4.0
then / if needed
  • recurrent with bradycardia or pauses → raise the rate: overdrive pacing or isoproterenol
avoid
  • amiodarone — prolongs the QT further

mechanism → management

  • Monomorphic VT = re-entry around fixed scar (prior MI, cardiomyopathy) → recurs predictably → ablation targets the circuit; ICD for death prevention
  • Polymorphic VT with normal QT = acute ischaemia or channelopathy → revascularise; beta-blocker
  • Torsades = early afterdepolarisations from prolonged repolarisation, worse at slow rates and after pauses → magnesium (suppresses EADs even with normal serum Mg), K⁺ repletion, increase HR (pacing) and remove the QT drug
  • Sympathetic drive sustains storm → beta-blockade (non-selective, e.g. propranolol), sedation
  • Wide-complex tachycardia + verapamil/diltiazem → vasodilation and negative inotropy in VT → collapse. Presume VT
  • AADs suppress but don’t save lives in structural heart disease → the ICD prevents death; drugs and ablation reduce shocks

acute management

graph TD
    A[Sustained VT/VF] --> B{Pulse and stable?}
    B -->|no| C[Defibrillate / synchronised DCCV + ACLS<br/>shock-refractory → IV amiodarone or lidocaine]
    B -->|yes| D{Morphology}
    D -->|monomorphic| E[DCCV or IV procainamide<br/>amiodarone or lidocaine second line]
    D -->|polymorphic| F{QT in sinus beats}
    F -->|normal| G[Ischaemia → urgent angiography<br/>IV beta-blocker, amiodarone or lidocaine]
    F -->|prolonged: torsades| H[IV magnesium, K⁺ ≥4.0<br/>stop QT drugs, overdrive pacing<br/>non-selective beta-blocker]
    C --> I{≥3 episodes in 24 h?}
    I -->|electrical storm| J[Non-selective beta-blocker + IV amiodarone<br/>sedation, early EP involvement, ablation]
DrugDoseNotes
amiodarone (arrest)300 mg IV push (150 mg if <45 kg), then 150 mgafter failed shock; not if torsades suspected (CCS)
lidocaine (arrest)100 mg IV push (50 mg if <45 kg), then 50 mgalternative to amiodarone
procainamide (stable VT)10 mg/kg over 20 min → 1–2 mg/min; slow if hypotensivefirst-line drug for stable monomorphic VT (CCS strong); fewer adverse events than amiodarone in PROCAMIO (2016)
amiodarone (stable VT / storm)150 mg over 10 min → 1 mg/min × 6 h → 0.5 mg/min × 18 h; storm target 1–2 g over 24 hsecond-line for stable VT
lidocaine (stable VT)1 mg/kg IV → 1–2 mg/minsecond-line; ischaemic VT
propranolol (storm)40 mg PO q6h if BP stablenon-selective preferred; esmolol to test tolerance
  • Polymorphic VT/VF with STEMI → emergency angiography and revascularisation
  • Electrical storm (≥3 episodes in 24 h): beta-blocker + IV amiodarone (strong), sedation/anaesthesia, treat HF and ischaemia, K⁺ ≥4.0 and Mg²⁺ ≥0.9–1.0 mmol/L, check ICD programming → ablation
  • Torsades refractory to Mg with bradycardia → temporary pacing to raise the rate
  • Digoxin toxicity with VA → digoxin-specific antibody fragments
  • Not useful/harmful: CCBs in wide-complex tachycardia of unknown origin; magnesium in VF not due to torsades; prophylactic lidocaine or amiodarone in AMI; high-dose adrenaline
  • Initial workup: ECG, electrolytes, troponin, echo, ICD interrogation; CMR if the cause isn’t clear (strong)
  • Post-arrest care, TTM, comatose post-arrest angiography → post-cardiac arrest care

long-term management

secondary prevention ICD

SituationICDStrength (CCS 2016)
cardiac arrest from VT/VF, no reversible causeyesstrong
sustained VT with significant structural heart disease, no reversible causeyesstrong
sustained VT/VF >48 h after MI or revascularisationconsiderweak
unexplained syncope + structural heart disease + inducible VT at EPSyesstrong
syncope + structural heart disease, VT/VF the likely cause, high recurrence riskconsiderweak
  • ICD over antiarrhythmics: ↓ mortality vs (mostly) amiodarone in AVID (1997)
  • Only if meaningful survival >1 year expected; no ICD when comorbidities make survival gain unlikely
  • VT/VF within 48 h of an acute MI = reversible → revascularise, no ICD on that basis
  • Revascularisation alone does not prevent recurrent monomorphic VT; no ICD in incessant VT/VF until the arrhythmia is controlled (both III, AHA)
  • Primary prevention ICD criteria (LVEF thresholds) → HFrEF management
  • Waiting period for ICD (e.g. ≤40 days post-MI, new cardiomyopathy) or explanted ICD → wearable defibrillator may be considered
  • Driving restrictions → fitness to drive (cardiac)

suppression of recurrent VT

  • Beta-blocker at maximally tolerated dose in all with structural heart disease (strong)
  • Sotalol or amiodarone first-line AAD (strong) — amiodarone more effective, more toxic. Doses → antiarrhythmics
  • Catheter ablation:
    • ischaemic cardiomyopathy, monomorphic VT despite sotalol/amiodarone → ablation (strong). Ablation beat AAD escalation for death, storm or appropriate shock in VANISH (2016)
    • ischaemic, first-line alongside beta-blocker → consider (conditional)
    • non-ischaemic cardiomyopathy → second line after AAD failure (lower success, often epicardial)
  • Refractory: mexiletine + amiodarone, dofetilide; then specialised ablation, stereotactic radiotherapy, cardiac sympathetic denervation
  • Optimise ICD programming (long detection, ATP) to cut shocks
  • Screen for psychological distress after shocks (strong)

frequent PVCs

  • PVC burden generally >15% with falling LVEF → suspect PVC-induced cardiomyopathy → ablation or beta-blocker/amiodarone; LVEF often recovers

inherited arrhythmia syndromes

SyndromeClueTreatmentICD
long QTprolonged QTc (≥480 ms supports diagnosis), syncope or arrest; high risk if QTc >500, LQT2/LQT3, symptom onset <10 ybeta-blocker if QTc >470 (strong), reasonable if <470; avoid QT-prolonging drugs; correct K⁺/Mg²⁺; mexiletine or cardiac sympathetic denervation if breakthroughafter arrest; recurrent events despite beta-blocker
Brugadacoved ST elevation in V1–V2 (type 1), spontaneous or provoked by procainamide/flecainide challengeavoid Na⁺-channel blockers; quinidine or epicardial ablation for recurrent shocksspontaneous type 1 + arrest, sustained VA or arrhythmic syncope. Drug-induced pattern only, asymptomatic → observe
CPVTexertional bidirectional or polymorphic VT, structurally normal heartbeta-blocker (strong); add flecainide or sympathetic denervation if breakthroughrecurrent VT/syncope despite therapy
short QTshort QTc, AF, family SCDquinidine; isoproterenol for stormafter arrest
  • Genetic counselling and testing in the proband; screen first-degree relatives (strong)
  • Unexplained SCD → postmortem including genetic testing; cardiology screening of the family
  • HCM, ARVC, sarcoid, myocarditis, LVAD and neuromuscular disease have disease-specific ICD criteria → hypertrophic cardiomyopathy, dilated cardiomyopathy

Prepared 2026-10-30. Not yet verified — check every number against the sources.

Key references

+3 more sources

Suggest a correction ventricular arrhythmias and sudden cardiac death